Gut-Brain Disorders Surge After Pandemic
'Healthcare providers should recognize post-COVID DGBI as part of the long COVID spectrum. These post-COVID gut problems appear more severe and require more medical care than similar pre-pandemic conditions,' Imran Aziz, MBChB, MD, honorary consultant gastroenterologist and senior clinical lecturer, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, England, told Medscape Medical News .
Aziz and colleagues surveyed a nationally representative sample of 4050 adults in the UK and the US in 2017 (pre-pandemic) and repeated the survey in 4002 adults in 2023 (post-pandemic).
The surveys included the Rome IV diagnostic questionnaire for DGBI and questions about nongastrointestinal somatic symptoms, anxiety and depression, quality of life, and healthcare use.
The 2023 survey also asked about COVID-19 infection and illness history.
The overall prevalence of DGBI (ie, meeting diagnostic criteria for at least one DGBI) increased significantly from the pre- to post-pandemic era (38% vs 47%; odds ratio [OR], 1.20), with similar findings independently noted in both countries.
From pre- to post-pandemic, the rise in DGBI was observed within the esophageal (9% vs 10%; OR, 1.16), gastroduodenal (12% vs 16%; OR, 1.45), and bowel domains (30% vs 33%; OR, 1.12).
Functional dyspepsia rose nearly 44% — from 8% to 12% (OR, 1.48) — and IBS increased 28% — from 5% to 6% (OR, 1.31).
The rise in DGBI has been seen in both men and women and across all adult age groups.
Multiple Factors at Play
Aziz told Medscape Medical News the uptick is probably due to not only the direct impact of SARS-CoV-2 infection on the gastrointestinal tract but also to the psychological stress associated with pandemic life.
'In this study, we found that COVID-viral related factors contributing to DGBI include number of infections, abdominal pain and/or diarrhea during COVID-19 infection, and long COVID,' he explained.
'We also observed increased mood disturbances among people with DGBI in the post-pandemic era, but this study did not determine the direction of causality. Previous studies have shown that in one third of DGBI cases the mood disturbance precedes gut symptoms, while in two third of cases gut symptoms precede mood disturbances,' Aziz noted.
The study was published online on July 30 in Clinical Gastroenterology and Hepatology .
The results are in line with a recent study that found the prevalence of IBS and chronic idiopathic constipation among US adults rose significantly during the COVID-19 pandemic, with a near doubling of the national rate of IBS over 2 years, as reported previously by Medscape Medical News .
Given a lack of high-quality clinical trials specifically for post-COVID DGBI management, 'healthcare providers should follow existing standard guidelines for functional dyspepsia and IBS,' Aziz advised.
'The established treatment protocols remain our best approach until more targeted research becomes available. It's also important to take a holistic approach. This means addressing not just the gut symptoms but also any accompanying mood disturbances. Many long-COVID clinics already provide this multiintegrated care model, which appears to be the most effective approach,' Aziz said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Glasgow hospice funding plea as it reveals £755k shortfall
A GLASGOW hospice has begun a fundraising campaign after revealing it faces a shortfall of more than three quarters of a million pounds. The Prince and Princess of Wales Hospice in Bellahouston Park is hoping 'the local community' will support its Vital Care Appeal. Chief Executive Rhona Baillie said: 'We provide free specialist palliative and end-of-life care to 1200 new patients and their families each year, both at the hospice at Bellahouston Park and in patients' own homes. 'We're doing everything we can to keep our costs to a minimum. We run our services efficiently, we're innovating with our fundraising, and we make every pound count. 'But despite our efforts, a significant funding gap remains.' (Image: Colin Mearns/Newsquest) The hospice is predicting a £755,000 shortfall in funding, citing the rise in demand for its services, patients' more complex needs and rising costs as the main pressures. Ms Baillie said that 'with local government funding just 30 per cent of running the hospice, the remaining 70 per cent comes from fundraising and donations' and added: 'We're not in crisis yet, but we need to act and that's why we are turning to our friends in the community for help.' Kirsty with her dad, Robert (Image: PPWH) Kirsty Dolan, 22, is supporting the appeal following the death of her dad, Robert, in the hospice in 2021. Robert was diagnosed with Parkinson's when he was 48 and Kirsty, who was only 10 at the time, along with her mum and older sister, became carers for him. In 2021, he visited the hospital for inpatient care. READ NEXT: Seeds of trees which survived Hiroshima help create new Glasgow garden Glasgow pupil heading for top art school after exam success 'We'll use King's Honours to keep battling for our Glasgow community' 'He had developed supranuclear palsy and needed specialist care,' said Kirsty. 'He was in the IPU for about a week where he just received the very best care you could imagine. 'We got to spend as much time with him as we could, and we even got to bring our dogs in for a visit. When he was nearing the end of his life, we all stayed over at the hospice in the family rooms so we could be close.' Kirsty also received support from the hospice's Family Support Service. 'I was really struggling,' she said. 'I was at breaking point. I emailed the hospice and the Family Support Service got in touch – and I have to say, it changed my life. "The team worked with me over a period of time and just helped me see things differently. ' It really was a lifeline, and I needed that support so much.' Glasgow Times readers helped raise the £21m needed for the new hospice, which opened in 2018, through our Brick by Brick Appeal. For more information on the Vital Care Appeal visit or call 0141 726 2660.
Yahoo
an hour ago
- Yahoo
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk (NVO) reported an earnings miss Wednesday, sending its stock down 4% in early trading, pressuring the stock further after a surprise management shake-up earlier in the year and sharply lowered guidance despite growing sales of its blockbuster GLP-1 drugs Ozempic and Wegovy. The stock is down more than 46% year to date as a result. CFO Karsten Munk Knudsen discussed some of the changes in recent weeks. He told Yahoo Finance that the leadership change — the ousting of CEO Lars Jørgensen and international head Mike Doustdar taking his place — was a surprise. "I was surprised about the changes of CEOs back in May," Knudsen said. "But ... looking at other companies ... when pressure is on, in terms of performance and competition, then it's not unusual that bosses and owners assess what's the right team to lead the company. In a macro setting I don't think its extraordinary, but in a Novo setting it was indeed surprising." The US market has also proven a challenge for Novo Nordisk, as it lost its lead despite a first-mover advantage to competitor Eli Lilly (LLY). Executives blame the compounding market, in which copycats are allowed under special circumstances, with telehealth platforms taking advantage of the loophole despite the FDA ending a shortage of GLP-1s that previously allowed copycats to freely sell on the market. Knudsen said the compounding market is about one-third of current GLP-1 prescriptions in the US market. On top of the competition and copycats, Novo Nordisk, like other big pharma names, has been targeted by the Trump administration to lower prices for consumers. It was one of 17 companies to receive a letter demanding lower costs for current and new products. "In reality, we're not that far apart in the sense that we also drive for affordable access in products that we supply. Our GLP-1 pricing is already rather low," Knudsen said, without revealing the actual numbers. Outgoing CEO Lars Jørgensen said on an earnings call Wednesday that its prices for Medicaid, for example, are already lower than in Europe. Those prices are not publicly available. The letter also asked the companies to price new drugs at the same low pricing found in other developed countries and to provide the lower cash prices more widely. Crunching cash numbers Some experts have expressed doubt about cash market success, however. Craig Garthwaite, a professor of strategy and healthcare at Northwestern University's Kellogg School of Management, posted on X in response to the Trump letters, questioning the strategy's viability. "How many customers do we believe have the ability (or willingness) to pay out of pocket for brand name drugs? A simple reading of the literature on increasing cost sharing suggests that people are not prepared to pay cash for these products — even if it is at the net and not the list price," Garthwaite said. But Knudsen noted that of its Wegovy patients in the US, 10% are paying cash through NovoCare, the direct-to-consumer channel, after it launched in March. "I am absolutely convinced that the cash channel is going to increase from here, and going to constitute a major part of the Wegovy business into the future," he said, adding that the overall cash market for GLP-1 in the US is already way above 10%. Knudsen referenced the compounding market, saying it provides insight into the potential, as those customers are cash-paying and represent one-third of the Wegovy market. But the cash price paid for copycats is significantly lower than the $499 per month available on NovoCare. Hims and Hers (HIMS), which Novo recently cut ties with over its refusal to stop selling compounded semaglutide, advertises prices as low as $199 per month for a 12-month plan of the copycat drug. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
an hour ago
- Bloomberg
FTC Sues to Block Edwards LifeSciences Medical Device Deal
The US Federal Trade Commission filed suit Wednesday to block Edwards Lifesciences Corp. from acquiring medical device maker JenaValve Technology Inc. In a complaint filed in Washington federal court, the FTC said the deal would hinder innovation for medical devices used to treat a serious heart condition known as aortic regurgitation, where blood pumped from the heart leaks back into the chamber
